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ABSTRACT 
 
It is widely known that nutritional deterioration in cancer patients is a strong predictor 
of patients’ treatment outcome and survival. To clarify this association, there is an increasing 
use of bioelectrical impedance analysis (BIA) to evaluate body composition and phase angle 
(PhA) in cancer. The aims of this review were: 1) to explore the efficacy of BIA for body 
composition analysis in cancer; 2) to determine the value of the implementation of BIA for 
evaluating outcomes in cancer in clinical practice and 3) to evaluate the relevance of assessing 
phase angle in oncology practice. PubMed, MedLine, CINAHL, EBSCO and Cochrane 
Library have been searched for relevant publications in English, until March 2017. The 
keywords used were “cancer”, “phase angle”, “body composition”, “BIA”, “outcomes”. 
Original research studies were thoroughly reviewed to identify strengths and limitations, to 
enable a better understanding of the mechanisms and support the use of BIA in the routine 
evaluation of cancer patients. The use of BIA and its derived parameters, most importantly 
PhA and body cell mass, provide practitioners with a sensitive, convenient, and non-invasive 
method for the evaluation of nutritional status, body cell mass and overall health status in 
cancer patients. BIA can assist practitioners in the evaluation of nutritional deterioration and 
risk of cachexia. PhA indicates indirectly the integrity of cell membrane, and thus potentially 
disease progression. The implementation of these parameters given by BIA should be 
encouraged as they may allow for timely adjustments of treatment regimens, and appropriate 
nutrition and medical intervention to improve Quality of Life and eventually prognosis. 
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RESUMO 
 
É globalmente conhecido que a deterioração nutricional em doentes oncológicos é um 
forte preditor do potencial resultado de um tratamento e de sobrevivência. Para clarificar esta 
associação, existe um incremento no uso da Análise Bioeléctrica por Bioimpedância (ABB) 
para avaliar a composição corporal e o ângulo de fase (AF) em oncologia. Os objectivos desta 
revisão são: 1) determinar o valor da implementação da ABB para avaliar o resultado em 
oncologia e na prática clínica; 2) determinar a relevância de avaliar o AF na prática clínica em 
oncologia. PubMed, MedLine, CINAHL, EBSCO e Cochrane foram pesquisadas com o 
propósito de seleccionar publicações relevantes em Inglês e publicadas até Março de 2017. As 
palavras chave foram “cancro”, “ângulo de fase”, “composição corporal”, “ABB” e 
“resultados”. Vários artigos científicos foram completamente revistos como intuíto de 
identificar os pontos fortes e fracos dos mesmos , para permitir assim uma melhor 
compreensão dos mecanismos que possam validar o uso de ABB numa avaliação rotineira de 
doentes oncológicos. O uso de ABB e seus derivados, principalmente o AF e massa celular, 
fornece aos clínicos um método sensivel, não-invasivo e conveniente para a avaliação 
nutricional destes doentes. ABB pode assim apoiar os clínicos numa avaliação de uma 
possível deterioração nutricional e risco de caquéxia. O AF indica inderectamente a 
integridade da membrana celular  e assim possivelmente a progressão da doença. A 
implementação destes parâmetros deve ser encorajada pois podem permitir ajustes em 
regimes terapêuticos e aporte nutricional. Promovendo assim uma possível melhor qualidade 
de vida e prognóstico. 
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INTRODUTION 
 
Undernutrition is consistently associated with cancer; in fact, historically through 
times until nowadays, weight loss is significantly incident among cancer patients and it does 
dictate a poorer tolerance to antineoplastic treatments and a shorter survival (Dewys et al, 
1980). Although its recognition as a strong prognostic predictor, undernutrition is still under-
diagnosed and under-assessed in clinical practice and therefore under-treated or even 
untreated. Notwithstanding, in Oncology as is other patient’ populations, recent data show 
that nutritional status may range from undernutrition to excess body weight to obesity 
(Ravasco et al, 2010). This occurs due to the high prevalence of overweight/obesity in 
western countries; this contributes to a high proportion of cancer patients with inadequate 
body mass index (BMI), e.g. ≥25kg/m2. Recent studies from our group show a prevalence of 
63% of overweigh/obesity in several cancer types, especially of the breast, prostate, 
gynecological and colon-rectum (Ravasco et al, 2010). Nevertheless, overweight/obesity does 
not overrule sarcopenia that may be concomitantly present; this new scenario of sarcopenic 
obesity has been consistently associated with a poor disease prognosis, since it may determine 
lower functional status, higher toxicity to antineoplastic treatments and lower survival (Martin 
et al, 2013).  
 Due to this diverse and new scenario in Oncology, new methods and techniques to 
assess nutritional status and body composition have been explored. Computerized 
Tomography (CT) scans at the level of the third lumbar vertebrae have recently been 
validated in Oncology to determine the quantity of body muscle and of fat mass. Moreover, 
CT scans also allow the verification of fat infiltration into muscle fibers (muscle attenuation); 
this parameter indicates that muscle contraction may be compromised, which translates in 
patients’ lower functional status. As already mentioned, another method for body composition 
assessment that may be integrated in clinical practice is BIA (Kyle et al, 2004), which is 
simple and quick, and provides data on fat mass, lean body mass, body fluid distribution and 
phase angle. PhA is an objective parameter that may indicate body tissues’ electric properties 
and therefore, cellular health and its metabolic performance (Gupta et al, 2008). It is thus 
considered not only a potential indicator of nutritional status, but also an indicator of overall 
disease status and prognosis.  
The present review will focus on the clinical value of PhA given by BIA for 
nutritional, metabolic and clinical assessment of cancer patients, and the potential 
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applicability in routine practice in the Oncology setting. For that we will 1) explore the 
potential significance of BIA for body composition analysis in cancer; 2) to determine the 
value of the implementation of BIA for evaluating outcomes in cancer in clinical practice and 
3) to evaluate the relevance of assessing phase angle in oncology practice. 
 
BIOELECTRICAL IMPEDANCE ANALYSIS (BIA) 
 
BIA is a non-invasive, easy-to-use, reproducible method, which can be conducted at 
the bedside (Kyle et al, 2004; Norman et al, 2012). Its principles are based on: 1) the passage 
of a very low voltage electric current through the body and 2) on the ability of the different 
body tissues’ conduction related with the electrical properties of tissues. Deriving from the 
resistance of the body cells to the passage of the electrical current, two values are obtained: 
Resistance (R) and Reactance (Xc): R is the opponent to the flow of an alternating electrical 
current through intracellular and extracellular ionic solutions, and Xc is the expression of the 
bioelectric properties of cell membranes and tissues’ interfaces (Paiva et al, 2011). The 
combination of resistance and reactance is called Impedance. The electric current passes 
mainly through tissues with high water content (fat-free mass - FFM) since bone and fat mass 
(FM) have high impedance, which determines a reduced conduction of the electric current 
(Norman et al, 2008). 
Both R and Xc may be measured at different frequencies, ranging from zero to an 
infinite frequency. At zero frequency, the electric current passes exclusively through the 
extracellular fluid, while at an infinite frequency, the current penetrates the cell membrane 
reflecting both intracellular and extracellular fluid (Paiva et al, 2011; Norman et al, 2008). 
Most single-frequency BIA equipments operate at a frequency of 50 kHz, which promotes the 
passage of the electric current through intra and extra cellular fluid at different proportions, 
depending on the penetrated tissue. Single-frequency BIA measures FFM and total body 
water (TBW), but it does not distinguish between intra (ICW) and extracellular water (ECW). 
Multi-frequency BIA devices can determine FFM, TBW, ICW and ECW (Kyle et al, 2004).  
In order to obtain body composition, impedance values need to be converted by means 
of validated equations that are specific to certain populations according to age, sex and 
ethnicity. Altered tissue conductivity and/or abnormal tissue hydration may result in incorrect 
body composition analysis by BIA, since validated equations for healthy populations may be 
inadequate for ill/hospitalized individuals (Paiva et al, 2011). Of note that BIA equations are 
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not able to predict body composition in patients with a BMI >34kg/m2 given the abnormal 
hydration, increased fat content and altered geometric tissue distribution. Therefore, in 
patients with chronic diseases, altered fluid balance and morbid obesity, BIA accuracy may be 
compromised; future validation studies are needed in order to evaluate BIA validity in these 
specific populations (Tisdale, 2010; Toso et al, 2000).  
 
 
PHASE ANGLE 
 
PhA is the relationship between raw impedance values: R and Xc, and it is calculated 
with the formula: arc tangent 
π
º
R
Xc 180
 . Subsequently, PhA has a clear advantage other BIA 
parameters, since it does not rely neither on regression predictive equations for body 
composition, nor on the assumption of a constant tissue hydration. Recently, PhA research has 
attained major interest since it seems to be a potential predictor of poor clinical outcome and 
mortality in various pathologies and clinical conditions, e.g. HIV, AIDS, hemodialysis, liver 
cirrhosis and cancer (Tisdale, 2010). In disease states, fluid disturbance may occur, as well as 
loss of cell membrane integrity, leading to alterations in tissues conductivity (Toso et al, 
2000; Toso et al, 2003). Given these structural changes, there may be altered impedance 
parameters since intra and extracellular fluid distribution is given by R, and cell membrane 
integrity is given by Xc. Ultimately, these changes are reflected on the PhA value, where 
lower values indicate poorer cell health, lower cellularity and loss of cell membrane integrity, 
reflecting worse cell function (Toso et al, 2000; Toso et al, 2003). Therefore, PhA expresses 
both the quality and quantity of soft tissues, being also suggested as a indicator of body cell 
mass (Gupta et al, 2004). 
PhA is determined with 3 main factors: age, gender and BMI. With ageing, PhA tends 
to decrease because of loss of skeletal muscle that translates into a reduced body reactance; on 
the other hand, resistance may increase due to a reduction on water content concomitantly 
with an increase in fat mass (Paiva et al, 2011. In what concerns gender, PhA is higher in men 
than women due to a greater muscle mass compartment. As for BMI, it has been observed that 
PhA may increase in higher BMIs because of the higher number of cells (adipocytes or 
muscle cells) (Toso et al, 2000). However, this relationship was only observed for a 
BMI<30kg/m2, whilst for a BMI >30kg/m2–40kg/m2 this relationship was not found and for 
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BMI >40Kg/m2, an inverse correlation was found. This may be explained by a loss of 
integrity of cell membranes caused by pro-inflammatory cytokines secreted by adipocytes 
and/or because of a shift of fluid balance in morbid obesity, characterized by augmented 
extracellular/intracellular fluid ratio. Therefore, PhA reference values, standardized for age, 
gender and BMI are mandatory for PhA analysis (Gupta et al, 2004).  
PhA has been explored as a potential indicator of undernutrition, functional status and 
disease prognosis in cancer. Interestingly, in disease-related malnutrition, electric properties 
of tissues may be disturbed leading to lower PhA; both a decrease in body cell mass in 
relation to extracellular mass, and an increase in the ratio extracellular/intracellular fluid may 
be reflected by PhA (Gupta et al, 2004; Gupta et al, 2004; Gupta et al, 2008). Furthermore, 
infection, inflammation or other clinical problems associated with a compromised health 
status, may all contribute to a low PhA which makes it a promising variable to take into 
consideration in cancer management, in nutrition and disease, clinical course and outcome.  
 
 
PHASE ANGLE: IMPACT ON CLINICAL OUTCOME 
 
Some studies explored the potential prognostic value of PhA in cancer, namely on 
long term Quality of Life (QoL), functional status and survival (Gupta et al, 2004; Gupta et al, 
2004; Gupta et al, 2008). The first studies that evaluated the impact of PhA on survival were 
retrospective and included patients with cancer of the colon-rectum, pancreas, breast and lung. 
The methodology was similar between studies: median PhA was used as the cut-off value 
within the study population. Patients with a PhA below the median value had a significantly 
lower survival vs patients with a PhA higher than the median value. In a study conducted in 
head-neck cancer patients in stages IIIB and IV, those whose PhA was <4,733º had a 
significantly higher risk for shortened overall survival vs. the remaining patients (19.6 months 
vs. 45 months) (Wladysiuk et al, 2016). Even though there was statistical significance in these 
findings, there are some limitations in their integration in the clinical setting: median PhA 
might not be applicable in other populations and it does not consider the three PhA 
determinants (age, gender and BMI). Therefore, improved methodology and study designs are 
mandatory to corroborate these findings: prospective studies and the PhA reference values 
should derive from healthy populations to assess the eventual deviation of PhA vs population 
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average values. In this sense, reference values were presented as percentiles standardized for 
PhA major determinants; Barbosa e Silva et al published PhA reference values for healthy 
Americans (n=1967 adults), stratified for age and gender. Later on, the reference values were 
published, stratified for age, gender and BMI, generated from a sample of 214,732 healthy 
German adults; to our knowledge these are the only PhA reference values stratified according 
to the three major PhA determinants (Gupta et al, 2009; Santarpia et al, 2009). 
In order to overcome the previously mentioned limitations, Norman et al conducted a 
prospective study on 399 cancer patients with different tumours, to assess the prognostic 
value of PhA on nutritional status, muscle function, QoL and & months survival (Norman et 
al, 2010). The 5th percentile was established as the cut-off and a new approach on PhA 
analysis was used; PhA values were standardized by creating a z-score: standardized PhA 
(SPhA)=(observed PhA–mean PhA)/SD PhA, in which mean and SD result from stratified 
values for age, gender and BMI. This approach did show that a PhA<5th percentile predicted a 
lower nutritional and functional status and an impaired QoL; moreover, it was also associated 
with a significantly higher 6 months mortality risk (OR: 4.0; 95% CI: 2.4, 6.8; p<0.001) and a 
37.4% probability of death (Norman et al, 2010). On the other hand, SPhA emerged as an 
independent predictor of impaired muscle function, malnutrition and 6 months mortality, 
showing a better performance than malnutrition assessed by Subjective Global Assessment; 
thus, the authors concluded that SPhA improved the prognostic value of PhA, clearly due to 
its ability to assess and quantify patients’ individual deviations from populations averages 
(Sanchez-Lara et al, 2012). 
Other studies explored the prognostic value of PhA by estimating SPhA. Paiva et al 
conducted a prospective study in cancer patients with various tumours: breast, gynecological, 
gastrointestinal, head-neck (Paiva et al, 2011). A low PhA corresponded to the SPhA’s 5th 
percentile of the normal population; by using this cutoff, patients with a low SPhA had a 
relative risk of 3.25 for mortality vs a SPhA ≥5th percentile (Paiva et al, 2011). The use of a 
heterogeneous patient population including several tumour types and the lack of comparison 
with other prognostic factors may be a limitation of this study in what concerns assessing the 
value of PhA as a potential prognostic predictor. Subsequently, Urbain P et al published a 
prospective study in hematological cancer patients submitted to allogeneic hematopoietic cell 
transplantation, aiming to investigate the validity of several nutritional parameters, including 
SPhA, Subjective Global Assessment (SGA) and previous weight change as independent 
predictors of outcome until 2 years after transplantation (Sanchez-Lara K et al, 2012). The 
cut-off for a low PhA was defined as the 25th quartile of the SPhA in the study population 
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calculated using gender-, age- and BMI-specific reference values for the German population. 
Results showed that PhA was an independent predictor for 2-year outcomes in these patients, 
having a superior performance than SGA and weight change’ history (Sanchez-Lara K et al, 
2012). Another approach was reports in a study that analyzed potential relationships between 
PhA and tumour volume in patients with non small cell lung cancer. The results supported the 
fact that tumour volumes were negatively correlated with PhA (r=-0.55; p<0.001), meaning 
that the PhA is closely associated with tumour burden for the host; this is of central 
importance to plan and prioritise early nutritional interventions, as it may indicate poor 
outcome at the time of diagnosis (Castanho et al, 2012). 
Recently, our group also performed a pilot study including 71 patients with various 
cancers at various stages, referred for Radiotherapy. PhA was compared with reference 
values, stratified by age and gender, and the 5th percentile of the reference population was 
established as the cut-off (data not shown). A low PhA was found in 16% of patients and of 
those, 90% had advanced disease (stages III/IV). Nutritional status by Patient Generated-
Subjective Global Assessment (PG-SGA), showed that 37% of patients were undernourished 
(moderately/severely). By crossing variables we found that 91% of patients with low PhA 
were undernourished (p<0.001) and had indication for urgent nutritional intervention. The 
PG-SGA score that indicates the need for nutritional intervention was stratified according to 
the 5th percentile of PhA; results showed that patients with a PhA <5th percentile had a 
significantly higher total PG-SGA score than those with a PhA >5th percentile [median: 10 IQ 
(7-17) vs median: 5 IQ (2-7), p=0.002]. In addition, QoL was also evaluated by the European 
Organization for the Research and Treatment of Cancer Quality of Life Questionnaire, version 
3.0 (EORTC-QLQ C30). PhA’s 5th percentile did anticipate a poorer global health perception 
(p=0.008) and global QoL scores (p=0.02); moreover, impaired physical, role and social 
functions were also found (p<0.05), as well as worse symptoms, e.g. fatigue, nausea and 
vomiting, anorexia and sleep disturbances (p<0.05). Based on our results, PhA may be useful 
to prioritize patients with critical need of nutritional intervention and for symptoms’ 
management, in order to maintain or even improve patients’ nutritional status, QoL and to 
optimize patients’ tolerance to treatments and with this, their efficacy.  
This year, a new study using multi-frequency evaluation was published with six 
different measures of PhA (5, 50 and 250 kHz in both sides of the body) in patients with 
advanced cancer. For all six PhA variables, a lower value was significantly associated with 
poorer overall survival (p<0.001). After adjusting for cancer type, performance status, weight 
loss and inflammatory markers, PhA remained independently associated with overall survival. 
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The authors concluded that regardless of the frequency and body sides, PhA represents an 
objective prognostic factor in the cancer care setting (Hui et al, 2017). 
 
 
PHASE ANGLE: FUTURE PERSPECTIVES 
 
The potential prognostic predictor value of PhA in cancer is seemingly important; the 
literature shows its relevance and its value for integration in clinical practice as an easy 
variable to assess in patients, thus clinical researchers need to work on the limitations found in 
published studies for future ones. First, a consensus needs to be found on the cut-off that 
defines a low PhA. The SPhA calculation seems to be the most reliable approach to be used, 
since it not only compares PhA values with reference values from the healthy population, but 
also measures patients’ individual deviation from a population average; however, the 
reviewed studies used different cut-offs to define a low PhA. While Paiva et al established a 
low PhA as the 5th percentile value of the reference population, Urbain P defined a low PhA 
as the 1st quartile of the sample population. In the later study, the authors did state that this 
cut-off was a study limitation, since the external validity of the results was compromised; 
thus, PhA values in this study were extremely low which did not allow the use of the 5th 
percentile as the cut-off. This may indicate that PhA values may vary, not only between 
different cancer stages, but also between different types of cancer. Therefore, future research 
should focus on the identification of a valid cut-offs to be applied in clinical practice; these 
studies should be conducted in homogeneous populations, in order to evaluate potential 
differences of PhA values in different cancers. 
Second the use of different BIA devices in between studies. Although Resistance and 
Reactance are raw impedance parameters, the impedance results may vary between different 
devices. Actually, PhA and Xc values have been compared between two different devices: 
Xitron 4000B® and Data Input BIA 2000S® and differences were found. Therefore, further 
investigation on the potential impact of BIA devices is required, in order to explore the need 
of impedance analyser-specific reference values, besides age, sex and BMI.  
Third, PhA does seem promising as a prognostic predictor in cancer; yet there are no 
studies investigating the effect of specific therapies, either nutritional, pharmacological or 
life-style/physical activity on PhA values. It is important to establish that PhA expresses 
cellular health/function given by the cell membrane integrity and the balance between intra 
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and extracellular fluid, as well as by the quantity of body cell mass. Randomized trials with 
specific treatments and outcomes may modulate these cell and metabolic variables. Then, 
PhA assumes a major role for an early determination of favorable or unfavorable outcome of 
adjuvant therapies, allowing for timely corrections and adaptations with clear benefits for 
patients, QoL and overall disease prognosis.  
The use of BIA and its derived parameters, most importantly Phase Angle and body 
cell mass, provide clinicians with a sensitive, non-invasive, easy to use method to evaluate 
body composition as well as overall health status in patients. BIA can assist practitioners in 
the evaluation of undernutrition, cachexia, disease progression, and cell metabolism and 
integrity, and based on this review, its use should be encouraged. The knowledge of all those 
parameters allow for adjustments in treatment regimens making them adequate and 
individualized, and therefore appropriate interventions to improve QoL and survival are a 
highly enthusiastic prospect. 
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Table 1. Studies on phase angle and outcomes in cancer patients 
Authors 
Population and study 
design 
PhA and BIA device Outcome Results 
Gupta et al 
2004 
52 patients 
Stage IV colorectal cancer 
Retrospective study 
Cut-off value: median PhA of  
study sample (5.57º) 
BIA device: BIA-101Q (RJL 
Systems Inc.®) 
Survival 
Median survival in patients with PhA5.57 was 
lower (8.6 mo, 95% CI: 4.8, 12.4; n=26) than in 
patients with a PhA>5.57 (40.4 mo, 95% CI: 21.9, 
58.8; n=26), p=0.0001. A PhA5.57 was 
associated with a relative risk increase of 10.75 
(95% CI: 1.92, 60.24), p=0.007. 
Gupta et al 
2004 
58 patients 
Stage IV pancreatic cancer 
Retrospective study 
Cut-off value: median PhA of the 
study sample (5.0) 
BIA device: BIA-101Q (RJL 
Systems Inc.®) 
Survival 
Median survival in patients with PhA5.0 was 
lower (6.3 mo, 95% CI: 3.5, 9.2; n=29) than in 
patients with a PhA>5.0 (10.2 mo, 95% CI: 9.6, 
10.8; n=29), p=0.02. Every one unit increase in 
PhA was associated with a relative risk of 0.69 
(95% CI: 0.58, 0.96), p=0.02 
Gupta et al 
2008 
259 patients 
Breast cancer 
Retrospective study 
Cut-off value: median PhA of the 
study sample (5.6º) 
BIA device: BIA-101Q (RJL 
Systems Inc.®) 
Survival 
Median survival in patients with PhA5.6 was 
lower (23.1 mo, 95% CI: 14.2, 31.9; n=129) than 
in patients with a PhA>5.6 (49.9 mo, 95% CI: 
35.6, 77.8; n=130), p=0.031. Every one unit 
increase in PhA was associated with a relative risk 
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of 0.82 (95% CI: 0.68, 0.99), p=0.041 
Gupta et al 
2009 
165 patients 
Stage IIIB+IV non-small 
cell lung cancer 
Retrospective study 
Cut-off value: median PhA of the 
study sample (5.3º) 
BIA device: BIA-101Q (RJL 
Systems Inc.®) 
Survival 
Median survival in patients with PhA5.3 was 
lower (7.6 mo, 95% CI: 4.7, 9.5; n=81) than in 
patients with a PhA>5.3 (12.4 mo, 95% CI:10.5, 
18.7; n=84), p=0.02. Every 1 degree increase in 
PhA was associated with a relative risk of 0.79 
(95% CI: 0.64, 0.97), p=0.02 
Norman et al 
2010 
399 patients 
Different cancers 
Prospective study 
Cut-off value: 5th percentile of 
sex, age and BMI-stratified 
reference values and SPhA, 
normalized for age, sex and BMI 
Function status 
QoL 
Survival 
5th percentile was associated with lower handgrip 
strength (p<0.0001), lower Karnofsky 
Performance Scale (0<0.0001) and poor QoL 
global score (p<0.0001) 
Paiva et al 
2011 
195 patients 
Different cancer locations, 
before the first 
chemotherapy course. 
Prospective study 
SPhA, normalized for age and sex 
Cut-off: 5th percentile of normal 
population (-1.65) 
BIA device: BIA Quantum 101 
(RJL Systems®) 
Survival 
Patients with a SPhA < -1.65 had a smaller 
survival rate than those with SPhA ≥ -1.65, 
p<0.001. SPhA<-1.65 showed a relative risk 2.35 
(95% CI: 1.41, 3.90; p=0.001) times higher for 
mortality, by comparison with a SPhA≥-1.65 
Sánchez-Lara et al 
2012 
119 patients 
Stage IIIB and IV lung 
cancer 
Prospective study 
Cut-off value: median PhA of the 
study sample (5.8)  
BIA device: Bodystat Quadscan 
4000® 
Survival 
QoL 
Median survival in patients with PhA5.8 was 
lower (11 mo, 95% CI: 5.9, 16.0) than in patients 
with a PhA>5.8 (17 mo, 95% CI: 12.1, 21.0), 
p=0.009. A marginal association was found 
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 between phase angle and QoL score for anorexia 
(p=0.08) 
Castanho et al 
2012 
30 patients 
Non small cell lung cancer  
Prospective Study 
BIA device: BIA 450 
Biodynamics 
Thoracic Computer Tomography 
device : HiSpeed LX; General 
Electric Medical Systems. 
Tumour volume 
Tumour volumes were negatively associated with 
PhA (r= -0.55; p<0.001). 
Braga da Silva et al 
2013 
43 patients 
Esophagus and stomach 
cancer 
Cross-sectional study 
Cut-off: 5th percentile of SPhA  
(-1.65) 
BIA device: not specified 
Nutrition status 
PhA was significantly different between well-
nourished patients (SGA A) and those with 
malnutrition (SGA B and SGA C) 
Paul et al 
2013 
105 patients 
Haematological cancer 
Prospective study 
SPhA, normalized for age, sex 
and BMI 
Cut-off: lower quartile of SPhA in 
the study sample (-2.26) 
BIA device: Body Scout 
instrument® 
Survival 
PhA was an independent predictor for 2-year 
overall mortality (HR: 1.97; 95% CI: 1.02-3.08, 
p=0.043), progression free-survival (HR: 1.91; 
95% CI: 1.00-3.50, p=0.039) and non-relapse 
mortality (HR: 3.18; 95% CI: 1.23-8.27, p=0.017) 
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Life; Lif  PhA: phase angle; SPhA: standardized phase angle; QoL=Quality of Life; 
 
 
 
            
Wladysiuk et al 
2016 
75 patients 
Stages IIIB and IV head-
neck cancer 
Prospective study 
Cut-off value: median PhA of the 
study sample (4.733) 
BIA Device: SFB7 BioImp v1.55 
analyzer 
 
Survival 
In patients whose PhA was <4.733, the risk of a 
shortened overall survival was significantly higher 
vs. remaining patients (19.6 months vs. 45 months, 
p= 0.0489, chi-square: 3.88, HR: 1.8856, 95% 
confidence interval : 1.0031 to 3.5446). 
David Hui et al 
2017 
366 patients  
Different types of cancers 
Prospective study 
BIA Device:  not specified 
Multifrequency evaluation: 5, 50 
and 250 kHz in both sides of the 
body (6 measures). 
Survival 
For all six PhA variables, a lower value was 
significantly associated with poorer overall 
survival (p<0.001). After adjusting for cancer 
type, performance status, weight loss and 
inflammatory markers, PhA remained 
independently associated with overall survival 
(HR 0.85 per degree increase, 95% confidence 
interval 0.72 – 0.99 ; P=0.048). 
